PRESS

DALLAS, TX - April 16, 2022 - Every day patients from around the country arrive in North Texas desperate for help, anxious for answers and hopeful for a cure. They come here for world-class medical treatment and to participate in one of the many clinical trials underway for a range of diseases from Alzheimer’s to cancer.

LONGVIEW, TX - April 9, 2022 – Picture this next time you visit a restaurant. The kitchen makes the food and a waiter delivers the dish to your table, but with an added complexity: the waiter negotiated the cost of your enchilada plate with the kitchen, and you’ll learn the price when you receive the check.

AUSTIN, TX - March 29, 2022 – The Texas Healthcare and Bioscience Institute (THBI) is welcoming Miranda Goodsheller as its new Director of Operations and Economic Development.  Goodsheller will be the organization’s first team member to focus not only on operational success but also on enhancing THBI’s economic development initiatives that support the growing Texas life science industry.

AUSTIN, TX, January 27, 2022 – An updated study from the Berkeley Research Group (BRG) shows more than half (50.5 percent) of total spending on brand-name prescription drugs goes to middlemen like pharmacy benefit managers (PBMs) and other stakeholders in the drug supply chain – not to drug manufacturers.

AUSTIN, TX - December 7, 2021 – The Texas Healthcare and Bioscience Institute (THBI) is welcoming Victoria Ford as its new President and CEO. Ford will be the organization’s second head executive following the retirement of Thomas Kowalski, who served as THBI’s President and CEO since its inception 25 years ago. Kowalski announced his retirement in August.

AUSTIN, TX – May 13, 2021 - The Texas Healthcare and Bioscience Institute, The Texas Association of Business, and the Texas Association of Manufacturers today issued a statement in response to the Biden Administration’s announcement in support of the World Trade Organization’s push to waive intellectual property protections for COVID-19 vaccines. The waiver, which has not yet been negotiated, could suspend existing patent and intellectual property protections, effectively forcing U.S. companies to hand over trade secrets and proprietary information and potentially resulting in safety and supply chain concerns.

AUSTIN, TX – April 19, 2021 - Texas Senate Bill 264(87R) proposes creating an agency called the Texas Research Consortium to Cure Infectious Diseases, or TRANSCEND for short. The goal of this proposed bill is to position Texas as a leader in the nation in preparing for and averting the next pandemic and other emerging infectious disease threats. In a just-released econometric study, TEConomy Partners reports on the impact the COVID-19 pandemic has had on the State of Texas and its citizens, as well as the potential economic benefits that would result from passage of SB 264, establishing TRANSCEND.

AUSTIN, TX – September 18, 2020 - Tom Kowalski, President and CEO of the Texas Healthcare and Bioscience Institute (THBI), issued a statement today in response to President Trump’s most recent executive order, “Lowering Drug Prices by Putting America First.” 

AUSTIN, TX – June 17, 2020 - The Biotechnology Innovation Organization (BIO) released new data on the bioscience industry in the United States.

As people around the globe continue to grapple with the COVID-19 coronavirus pandemic, a number of Texas biotech firms and researchers say they are answering the call to combat the spread of the illness. (March 16, 2020)

mySA and San Antonio Express-News op-ed by THBI President and CEO, Tom Kowalski. (July 15, 2019)

TribTalk op-ed by THBI President and CEO, Tom Kowalski on the new driving force of the Texas economy. (April 16, 2019)

TribTalk op-ed by Texas Comptroller, Glen Hegar. (December 2018)